Who Could Buy Bristol-Myers Squibb? - Fool.com -BoardProspects

Who Could Buy Bristol-Myers Squibb?

Fool.com Feb 25 2017 BoardNews

Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol-Myers Squibb ( NYSE:BMY ) , a $90 billion-market-cap biopharma that's carving out an important leadership position in immuno-oncology. If past is prologue, Icahn's about to start advocating for big changes at Bristol-Myers Squibb, and those could include an outright sale. Finding a buyer, however, might not be easy...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- The Other Duty of Corporate Governance also categorized in BoardNews
- Corporate Boards: Shifting From Aging Men To New Generation Of Women? also categorized in BoardNews
- Public Companies' Public Enemies also published in Fool.com
- Getting Gen-Y on Boards (of Directors) also categorized in BoardNews
- Germany's Corporate Governance Problem also categorized in BoardNews
- Have the Swiss Gone Cuckoo? also categorized in BoardNews
- Taiwan Court Orders Reinstatement Of Two CPDC Board Candidates As Contested Vote Nears also categorized in BoardNews
- Here's How Carl Icahn's Portfolio Is Changing also written by Todd Campbell
- Why Should We Care About Corporate Interlocks? also categorized in BoardNews
- Why Valeant Pharmaceuticals Is Down 10% Today also written by Todd Campbell

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
Topics Mentioned
- Leadership
Authors
- Todd Campbell